HARP News and Press, Harpoon Therapeutics Inc. From 06/17/20

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferen...

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate i...

Gainers: Cemtrex (NASDAQ: CETX )  +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this Read more ...

The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts.   Initial safety data showed that HPN424 is generally well-tolerated, and cytokine-related adverse events have been transient and manag...

SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the Amer...

Harpoon Therapeutics (NASDAQ: HARP ): Q1 GAAP EPS of -$0.51 misses by $0.16 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVie Abstract for HPN424 interim Phase 1 data accepted for presentation at ASCO20 Virtual SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Harpoon...

Thinly traded micro cap Harpoon Therapeutics ( HARP +8.6% ) is up average volume in reaction to its announcement that the first patient has been dosed in a Phase 1/2 clinical trial evaluating candidate HPN217 in patients with relapsed/refractory multiple myeloma. More news on: Harpoo...

SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focu...